摘要
目的探讨熊去氧胆酸联合甘草酸二铵肠溶胶囊对慢性乙肝患者血清炎症因子、肝纤维化及不良反应的影响。方法选取2022年4月至2025年4月九江市第一人民医院收治的80例慢性乙肝患者,以随机数字表法分成两组,各40例。对照组行甘草酸二铵肠溶胶囊治疗,观察组行熊去氧胆酸联合甘草酸二铵肠溶胶囊治疗。治疗4周后,对比两组血清炎症因子、肝纤维化指标和不良反应。结果治疗后,观察组超敏C反应蛋白(hs-CRP)为(3.05±0.31)mg/L,干扰素γ(IFN-γ)为(8.96±0.85)pg/mL,血清透明质酸(HA)为(155.18±7.54)ng/mL,Ⅲ型前胶原(PC-Ⅲ)为(156.11±6.64)μg/L,Ⅳ型胶原(Ⅳ-C)为(102.52±5.46)μg/L,层粘连蛋白(LN)为(153.04±6.92)μg/L,均低于对照组的(4.42±0.53)mg/L、(10.14±0.94)pg/mL、(175.43±3.46)ng/mL、(169.16±3.01)μg/L、(113.40±6.08)μg/L、(171.34±6.99)μg/L,有统计学差异(t=14.112、5.889、15.438、11.321、8.421、11.767,P均<0.001);两组不良反应比较无统计学差异(P>0.05)。结论采用熊去氧胆酸联合甘草酸二铵肠溶胶囊治疗慢性乙肝患者,可显著降低炎症因子水平,改善肝纤维化,且安全性良好。
Objective To investigate the effect of ursodeoxycholic acid combined with diammonium glycyrrhizinate enteric-coated capsules on serum inflammatory factors,liver fibrosis and adverse reactions in patients with chronic hepatitis B.Methods During the period of April 2022 to April 2025,80 cases of chronic hepatitis B who admitted to Jiujiang First People'Hospital were assigned to two groups with random numerical table method,with 40 cases in each group.The patients of control group were treated with diammonium glycyrrhizinate enteric-coated capsules,and on this basis,the patients of observation group additionally took ursodeoxycholic acid.The comparisons were made on serum inflammatory factors,indexes of liver fibrosis,and adverse reactions in both groups after treatment for 4 weeks.Results After treatment,the level of high-sensitivity C-reactive protein(hs-CRP)in the observation group was(3.05±0.31)mg/L,interferon-γ(IFN-γ)was(8.96±0.85)pg/mL,serum hyaluronic acid(HA)was(155.18±7.54)ng/mL,type Ⅲ procollagen(PC-Ⅲ)was(156.11±6.64)μg/L,type Ⅳ collagen(Ⅳ-C)was(102.52±5.46)μg/L,and laminin(LN)was(153.04±6.92)μg/L,which were all lower than those in the control group[(4.42±0.53)mg/L,(10.14±0.94)pg/mL,(175.43±3.46)ng/mL,(169.16±3.01)μg/L,(113.40±6.08)μg/L,and(171.34±6.99)μg/L],with statistically significantly differences(t=14.112,5.889,15.438,11.321,8.421,and 11.767,all P<0.001).There was no statistical difference in adverse reactions between the two groups(P>0.05).Conclusion The combination regimen of ursodeoxycholic acid combined with diammonium glycyrrhizinate enteric-coated capsules in the clinical treatment of chronic hepatitis B patients can significantly reduce the levels of inflammatory factors and improve liver fibrosis,which has good safety.
作者
邵文华
卢仁隆
王高明
何伟平
SHAO Wenhua;LU Renlong;WANG Gaoming;HE Weiping(Second Department of Gastroenterology,Jiujiang First People's Hospital,Jiujiang Jiangxi 332000,China)
出处
《天津药学》
2025年第9期1042-1045,共4页
Tianjin Pharmacy
关键词
慢性乙肝
甘草酸二铵肠溶胶囊
熊去氧胆酸
炎症因子
肝纤维化
Chronic hepatitis B
Diammonium glycyrrhizinate enteric-coated capsules
Ursodeoxycholic acid
Inflammatory factors
Liver fibrosis
